Loading
Biolife Solutions Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 23 Oct 2023.
Biolife Solutions Inc: what insiders have been doing
Every trade that managers of Biolife Solutions Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, 105 filings were filed, from 14 insiders.
There is no open-market purchase to report; the filings show 36 sales worth €28.6M by 10 insiders. The totals exclude 1 filing filed without an amount. Biggest ticket of the year: €13.3M, sold by Casdin Partners Master Fund, L.P. and made public on 21 May 2026 (0.91% of market cap).
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (5,813 companies, median 19 filings), a count of 105 filings is above the norm. Over the whole record (from 2021), the tally stands at 4 purchases and 413 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 96.2 m USD and net income of -4.6 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
715
Thresholds
n/a
Buy Volume
€12M
4 ops. · all time
Sell Volume
€101M
413 ops. · all time
Who traded when
BuySaleSarah Aebersold22 sales
Karen A. Foster20 sales
Aby J. Mathew19 sales
Todd Berard19 sales
Troy Wichterman19 sales
Sean Werner9 sales
+4 other insiders
Since the insiders bought
- +104.8%Entry US$12.60 · Close at T+365 US$25.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Biolife Solutions Inc Hold (neutral), based on 4 analysts. Average price target: US$31.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 14,406 of 24,161 companies
45.8
score / 100
Value34
Quality57
FCF yld0.0%
Earn yld-0.2%
EV/EBITDA·
ROE13%
Gross mgn65%
Net mgn-4.8%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$38.61
Analyst consensus
4 analystsHold
US$31.00Target US$31.00(-20%)US$31.00
Income statement
RevenueUS$96.2M
Gross profitUS$62.1M65% margin
EBITDA-US$11.9M-12% margin
Net income-US$4.6M54.3% margin
Valuation
PER (trailing)39.0x
PER (forward)117.0x
P/Book4.5x
Beta1.82
Balance sheet & cash
Market capUS$1.9B
Total debtUS$17.9M
Free Cash FlowUS$416k
Debt / Equity4%
Profitability & ownership
ROE12.8%
ROA0.3%
% insiders2.6%
% institutions105.5%
Last declaration on 8 October 2026
Declarations715 total
76,204 sharesCommon StockSEC:0001193125-26-418329:0
45,838 sharesCommon StockSEC:0001193125-26-418315:0
194,786 sharesCommon StockSEC:0001193125-26-418308:3
45,838 sharesCommon StockSEC:0001193125-26-418304:0
62,300 sharesCommon StockSEC:0001193125-26-418329:1
95,933 shares@ US$38.610.20% mcap62.4% of flowCommon StockSEC:0001193125-26-418329:2
256,000 sharesCommon StockSEC:0001193125-26-418329:3
53,156 sharesCommon StockSEC:0001193125-26-418328:0
57,995 sharesCommon StockSEC:0001193125-26-418327:0
26,857 sharesCommon StockSEC:0001193125-26-418325:0
13,871 sharesCommon StockSEC:0001193125-26-418323:0
225,670 sharesCommon StockSEC:0001193125-26-418321:0
237,460 sharesCommon StockSEC:0001193125-26-418321:1
364,872 shares@ US$38.610.74% mcap67.7% of flowCommon StockSEC:0001193125-26-418321:2
826,454 sharesCommon StockSEC:0001193125-26-418321:3
15,046 sharesCommon StockSEC:0001193125-26-418319:0
44,943 sharesCommon StockSEC:0001193125-26-418316:0
40,192 sharesCommon StockSEC:0001193125-26-418315:1
70,000 shares@ US$38.610.14% mcap56.3% of flowCommon StockSEC:0001193125-26-418315:2
404,608 sharesCommon StockSEC:0001193125-26-418315:3
38,198 sharesCommon StockSEC:0001193125-26-418308:0
40,192 sharesCommon StockSEC:0001193125-26-418308:1
46,170 shares@ US$38.610.094% mcap47.3% of flowCommon StockSEC:0001193125-26-418308:2
48,232 sharesCommon StockSEC:0001193125-26-418304:1
71,226 shares@ US$38.610.15% mcap96.4% of flowCommon StockSEC:0001193125-26-418304:2
25 of 715 declarations
About Biolife Solutions Inc
BioLife Solutions Inc. is a U.S.-based company listed on the Nasdaq under the ticker BLFS in the United States. The company focuses on bioproduction tools and services for the cell and gene therapy (CGT) industry, with an emphasis on protecting cell integrity, improving manufacturing reproducibility, and reducing risk across storage, transport, and processing workflows. In practical terms, BioLife sells specialized products used by biopharma customers to preserve the viability of sensitive biological material through critical steps in the CGT supply chain. Its current messaging and filings consistently describe the company as a developer and supplier of cell processing tools and services for the CGT market.([biolifesolutions.com](https://www.biolifesolutions.com/?utm_source=openai))
BioLife has a long operating history and evolved over time from a more narrowly focused preservation-products company into a broader bioproduction platform serving advanced therapies. The company is headquartered in Bothell, Washington, where it also maintains manufacturing, R&D, marketing, and administrative functions. That footprint gives BioLife a strong operational base in the U.S. biotech corridor while serving a customer base that extends well beyond the domestic market.([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026012294/blfs-20251231.htm?utm_source=openai))
Read moreShow less
Its core business lines include biopreservation media, cell-culture optimization products, closed-system filling and storage solutions, and related shipping and handling technologies. Well-known product families include CryoStor and HypoThermosol, alongside complementary solutions aimed at preserving cell quality, lowering contamination exposure, and supporting aseptic manufacturing. The strategic appeal of BioLife lies in the fact that it is not competing as a broad pharma manufacturer; instead, it occupies a specialized enabling layer in the CGT ecosystem, where process reliability and regulatory validation matter more than scale alone.([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026013277/a2025blfsinvestorpresent.htm?utm_source=openai))
From a competitive standpoint, BioLife appears well positioned as a niche leader. Its products are embedded in demanding CGT workflows, and investor materials indicate meaningful traction across clinical trials and approved therapies. That kind of embedded usage can create sticky customer relationships, higher switching costs, and a defensible role in an industry where manufacturing complexity remains a major bottleneck. The company’s market position is therefore best understood as a high-value infrastructure supplier to the advanced-therapy value chain rather than a conventional life-sciences vendor.([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026013277/a2025blfsinvestorpresent.htm?utm_source=openai))
Recent developments have reinforced the strategic shift toward higher-quality revenue and profitability. BioLife reported full-year 2025 results on February 26, 2026, followed by first-quarter 2026 results on May 7, 2026. The company also issued 2026 guidance and continued to highlight growth in its core CGT franchise. For investors following insider activity and SEC Form 4 filings, BLFS combines an innovation-driven business model, exposure to the long-term CGT theme, and a Nasdaq listing in the United States with a more focused, margin-oriented portfolio after recent portfolio adjustments.([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026012264/blfsq42025earningsrelease.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
